1.0 2009-07-15 20:44:41 UTC 2026-05-14 16:37:35 UTC T3D2669 Zoledronate SmallMolecule Zoledronate belongs to the bisphosphonates, a subclass of organic phosphonic acids and derivatives within the organic compounds. It is an exogenous solid with the formula C5H10N2O7P2 and an average molecular weight of 272.09 g/mol. This compound is used as a drug (PMC10692760) and a bone density conservation agent (PMC10692760), specifically within healthcare, pharmaceuticals, and veterinary products for the treatment of bone diseases. It is administered via intravenous exposure. Zoledronate targets farnesyl pyrophosphate synthase (FDPS), geranylgeranyl pyrophosphate synthase (GGPS1), and matrix metalloproteinase-14 (MMP14). Its action on bone tissue is partly based on its affinity for hydroxyapatite in the bone mineral matrix. As a nitrogen-containing bisphosphonate, it acts as an analogue of isoprenoid diphosphate lipids to inhibit FPP synthase in the mevalonate pathway, which prevents the biosynthesis of isoprenoid lipids (FPP and GGPP) in osteoclasts. Therapeutically, zoledronate is used to treat osteoporosis (PMC10560398, PMC12051078, PMC12068388, PMC12896522, PMC2971711, PMC4307702), hypercalcemia (PMC10547673, PMC12061736), multiple myeloma (PMC1779467, PMC3699134, PMC8951013), breast cancer (PMC1779467), prostate cancer (PMC1779467), lung cancer (PMC1779467), cancer (PMC3688704), and renal cell carcinoma (PMC11029699). It has demonstrated therapeutic effects on colorectal cancer (PMC5384426), arrhythmia (PMC12409151), pain (PMC5037694, PMC9645513), multiple myeloma (PMC3722725, PMC5740853), and breast cancer (PMC3480876, PMC4293349, PMC4723356). Reported adverse effects associated with the compound include fever (PMC2971711, PMC8533546) and acute renal failure (PMC13228822). Drug Synthetic Toxin Organic Compound Drug Antihypocalcemic Agent Bisphosphonate Bone Density Conservation Agent Antiresorptive Metabolite Synthetic Compound Human Neurotoxin (1-Hydroxy-2-(1H-imidazol-1-yl)ethylidene)bisphosphonic acid (1-Hydroxy-2-imidazol-1-ylethylidene)diphosphonic acid Aclasta Reclast ZOL zoledronic acid Zoledronic acid Zometa Zometa Concentrate C5H10N2O7P2 272.0896 271.996323708 [1-hydroxy-2-(1H-imidazol-1-yl)-1-phosphonoethyl]phosphonic acid zoledronate 118072-93-8 OC(CN1C=CN=C1)(P(O)(O)=O)P(O)(O)=O InChI=1S/C5H10N2O7P2/c8-5(15(9,10)11,16(12,13)14)3-7-2-1-6-4-7/h1-2,4,8H,3H2,(H2,9,10,11)(H2,12,13,14) XRASPMIURGNCCH-UHFFFAOYSA-N Organic compounds Organic acids and derivatives Organic phosphonic acids and derivatives Bisphosphonates Bisphosphonates Azacyclic compounds Heteroaromatic compounds Hydrocarbon derivatives N-substituted imidazoles Organic oxides Organic phosphonic acids Organonitrogen compounds Organooxygen compounds Organophosphorus compounds Organopnictogen compounds Aromatic heteromonocyclic compound Azacycle Azole Bisphosphonate Heteroaromatic compound Hydrocarbon derivative Imidazole N-substituted imidazole Organic nitrogen compound Organic oxide Organic oxygen compound Organoheterocyclic compound Organonitrogen compound Organooxygen compound Organophosphonic acid Organophosphorus compound Organopnictogen compound Aromatic heteromonocyclic compounds 1,1-bis(phosphonic acid) imidazoles Detected and Not Quantified Exogenous Cytoplasm Membrane Zoledronate Pathway Zoledronate Action Pathway SMP0000107 Zoledronate Action Pathway SMP0126324 Zoledronate Drug Metabolism Pathway SMP0145442 Solid White powder. solubility Sparingly soluble logp -4.2 logp -0.93 ALOGPS logs -1.92 ALOGPS solubility 3.27e+00 g/l ALOGPS logp -3.9 ChemAxon pka_strongest_acidic 0.66 ChemAxon pka_strongest_basic 6.67 ChemAxon iupac [1-hydroxy-2-(1H-imidazol-1-yl)-1-phosphonoethyl]phosphonic acid ChemAxon average_mass 272.0896 ChemAxon mono_mass 271.996323708 ChemAxon smiles OC(CN1C=CN=C1)(P(O)(O)=O)P(O)(O)=O ChemAxon formula C5H10N2O7P2 ChemAxon inchi InChI=1S/C5H10N2O7P2/c8-5(15(9,10)11,16(12,13)14)3-7-2-1-6-4-7/h1-2,4,8H,3H2,(H2,9,10,11)(H2,12,13,14) ChemAxon inchikey XRASPMIURGNCCH-UHFFFAOYSA-N ChemAxon polar_surface_area 153.11 ChemAxon refractivity 52.16 ChemAxon polarizability 20.1 ChemAxon rotatable_bond_count 4 ChemAxon acceptor_count 8 ChemAxon donor_count 5 ChemAxon physiological_charge -2 ChemAxon formal_charge 0 ChemAxon Intravenous. Poorly absorbed (oral absorption is about 1% of what intravenous absorption is). The action of zoledronate on bone tissue is based partly on its affinity for hydroxyapatite, which is part of the mineral matrix of bone. Zoledronate also targets farnesyl pyrophosphate (FPP) synthase. Nitrogen-containing bisphosphonates such as zoledronate appear to act as analogues of isoprenoid diphosphate lipids, thereby inhibiting FPP synthase, an enzyme in the mevalonate pathway. Inhibition of this enzyme in osteoclasts prevents the biosynthesis of isoprenoid lipids (FPP and GGPP) that are essential for the post-translational farnesylation and geranylgeranylation of small GTPase signalling proteins. This activity inhibits osteoclast activity and reduces bone resorption and turnover. In postmenopausal women, it reduces the elevated rate of bone turnover, leading to, on average, a net gain in bone mass. Zoledronate does not inhibit human P450 enzymes in vitro and does not undergo biotransformation in vivo. Route of Elimination: In 64 patients with cancer and bone metastases, on average (± s.d.) 39 ± 16% of the administered zoledronic acid dose was recovered in the urine within 24 hours, with only trace amounts of drug found in urine post-Day 2. Half Life: 146 hours No indication of carcinogenicity to humans (not listed by IARC). For the treatment of hypercalcemia of malignancy. Also for the treatment of patients with multiple myeloma and patients with documented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy. In May of 2007, the drug was approved for treatment of Paget's Disease. #<HealthEffect::ActiveRecord_Associations_CollectionProxy:0x00007f3bbff24cf0> There is no experience of acute overdose. Two patients received zoledronate (32 mg) over 5 minutes in clinical trials. Neither patient experienced any clinical or laboratory toxicity. Overdosage may cause clinically significant hypocalcemia, hypophosphatemia, and hypomagnesemia. DB00399 HMDB14543 68740 CHEMBL924 61986 46557 ZOLEDRONATE Zoledronic Acid ZOL Zoledronate 18048412 17878149 11870242 16000365 BE0000776 The action of zoledronate on bone tissue is based partly on its affinity for hydroxyapatite, which is part of the mineral matrix of bone. Zoledronate also targets farnesyl pyrophosphate (FPP) synthase. Nitrogen-containing bisphosphonates such as zoledronate appear to act as analogues of isoprenoid diphosphate lipids, thereby inhibiting FPP synthase, an enzyme in the mevalonate pathway. Inhibition of this enzyme in osteoclasts prevents the biosynthesis of isoprenoid lipids (FPP and GGPP) that are essential for the post-translational farnesylation and geranylgeranylation of small GTPase signalling proteins. This activity inhibits osteoclast activity and reduces bone resorption and turnover. In postmenopausal women, it reduces the elevated rate of bone turnover, leading to, on average, a net gain in bone mass. Inhibitory 0.00007 uM BindingDB 12578 Inhibitory 0.0859 uM BindingDB 12578 IC50 0.00024 uM BindingDB 12578 IC50 0.003 uM BindingDB 12578 IC50 0.0041 uM BindingDB 12578 IC50 0.1 uM BindingDB 12578 IC50 0.11 uM BindingDB 50135836 IC50 0.13 uM BindingDB 12578 IC50 0.475 uM BindingDB 12578 IC50 0.4753 uM BindingDB 12578 BE0004801 BE0003570 Inhibitory 2.7 uM BindingDB 12578 IC50 97 uM BindingDB 12578 BE0003692 IC50 12.6 uM BindingDB 12578